Cancer treatment is undergoing a quiet revolution. Increasingly, what matters most is not where a tumour begins, but what is ...

Eli Lilly has agreed to spend some more of the cash raked in from its fast-growing incretin therapies for obesity and ...

Eli Lilly is rumoured to be planning to spend some more of the cash raked in from its fast-growing incretin therapies for ...

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in chronic ...

Boehringer Ingelheim has announced it is expanding its global Computational Innovation footprint with a new centre dedicated ...

Belgium's UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona Therapeutics and ...

Digital health companies, clinical trial technology providers, and life sciences suppliers continued to invest in senior ...

President Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of ...

In this week's second major AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, designed to ...

Eli Lilly says it has the safety data it needs to shore up the recent speedy approval of its oral obesity therapy Foundayo, ...

The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety ...

Medicines are uniquely vulnerable to disruptions caused by conflict, as unlike many other goods, they are tightly regulated ...